Analyst Consensus ?
ConsensusBuy26 ratings
Bullish2492.3%
Neutral27.7%
Bearish00.0%
Ascendis Pharma A/S · ASND · FY2026 Q1 · Calendar Q2 2026
Ascendis Pharma tops Q1 EPS, YUVIWEL approved, full-year guidance maintained
Ascendis' first quarter showed improving profitability and balance-sheet strength: EUR 25 million operating profit, EUR 573 million cash, a $187.5 million PRV sale, and full redemption of convertible notes, alongside an EPS beat and FDA approval of YUVIWEL, its fourth approved product. Management's confidence rests on YORVIPATH dose escalation and patient growth (6,300+ U.S. patients, 35 countries), the YUVIWEL launch, and a deep TransCon pipeline. Against that, revenue of $284.9M missed the $308.9M consensus by about 8%, and the stock drifted roughly -14.5% after the report even as analysts kept targets near a $317 consensus versus the ~$226 current price. The bull case is supported by product breadth and execution, but tempered by the revenue miss, the subsequent negative drift, and unresolved regulatory, reimbursement, and free-drug-program items analysts flagged for coming quarters.
Reported Before market openNASDAQHealthcare
$14.01B market cap
90quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.32
Consensus $0.19
EPS surprise
+70.6%
Reported versus consensus
Reported revenue
$284.9M
Consensus $308.9M
Revenue surprise
-7.8%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+4.3%
Event window
SPY move
-0.3%
Same window
Abnormal move
+4.6%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
-14.5%
Up to 20 sessions
ASNDSPY benchmark
Ask FN2 about ASND FY2026 Q1
Transcript, numbers and history already loaded
Why did ASND rise 4.3% after beating EPS estimates in FY2026 Q1?What changed in ASND's guidance and outlook in FY2026 Q1?Give me the bull and bear case for ASND after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Ascendis reported FY2026 Q1 with EPS of $0.32 versus consensus of $0.1876 (+70.6% surprise), while revenue of $284.9M missed the $308.9M estimate (-7.8%). The FDA approved YUVIWEL, adding a fourth product. Management sold the priority review voucher for $187.5M, completed a NASDAQ direct listing with full redemption of convertible notes, and discontinued internal oncology development of TransCon IL-2 beta/gamma. Guidance was maintained. The stock rose 4.6% in the reaction window with 1.8x normal volume, then drifted -14.5% subsequently.
Guidance delta
Management maintained its guidance (sentiment: maintained); no numeric change was reported. The full-year outlook was described as upbeat, focused on continued commercial and clinical milestones.
Key takeaways
- FDA approval of YUVIWEL adds a fourth product, bringing approved TransCon products to three across four rare endocrine indications.
- Q1 revenue of EUR 247 million with operating profit of EUR 25 million and cash balance of EUR 573 million.
- YORVIPATH now treats over 6,300 patients in the U.S. and is available in 35 countries with more than 2,700 prescribers.
- Hypochondroplasia combination therapy showed triple efficacy versus monotherapy with high patient retention.
- Sold its priority review voucher for $187.5 million in cash, completed a NASDAQ direct listing and fully redeemed its convertible notes.
- Quarterly guidance was maintained.
Management priorities
- Global expansion of YORVIPATH, including higher dosing to 60 mcg in the U.S. and new market launches.
- International rollout of YUVIWEL via early access programs, with pursuit of EU label approval in Q4 2026.
- Label expansion of YUVIWEL to infants and additional geographic regions.
- Continue combination therapy development for hypochondroplasia and growth hormone indications.
- Advance the TransCon semaglutide partnership with Novo Nordisk and move TransCon anti-VEGF toward clinic entry.
Follow ASND with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$225.6Current
$136Low
$272.3Average
$344High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 26, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 15, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Sep 2, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Sep 1, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Sep 1, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 31, 2026 |
| Jefferies | Buy | Buy | Maintain | Aug 31, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Aug 31, 2026 |
| B of A Securities | Buy | Buy | Maintain | Aug 31, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 14, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 14, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 14, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 8, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Oct 13, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2025 |
| UBS | Buy | Buy | Maintain | Aug 8, 2025 |
| Citigroup | Buy | Buy | Maintain | Aug 8, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2025 |
| Credit Suisse | Neutral | Neutral | Maintain | Apr 28, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 17, 2023 |
| Cowen & Co. | Perform | Market Perform | Maintain | Jan 6, 2022 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 1, 2021 |
| Berenberg | Buy | Buy | Maintain | Dec 17, 2020 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Jan 24, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 30, 2018 |
| Bank of America | Buy | Buy | Maintain | Jan 25, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $225.6. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $344 | $239.77 | +52.5% | Sep 16, 2026 |
| Raymond James | Martin Auster | $287 | $264.92 | +27.2% | Sep 15, 2026 |
| H.C. Wainwright | Analyst unavailable | $344 | $260.81 | +52.5% | Sep 10, 2026 |
| Oppenheimer | Leland Gershell | $312 | $260.25 | +38.3% | Sep 1, 2026 |
| Morgan Stanley | Maxwell Skor | $273 | $263.04 | +21.0% | Sep 1, 2026 |
| Jefferies | Analyst unavailable | $330 | $265.26 | +46.3% | Aug 31, 2026 |
| Stifel Nicolaus | Analyst unavailable | $326 | $265.32 | +44.5% | Aug 31, 2026 |
| UBS | Analyst unavailable | $345 | $247.91 | +52.9% | Aug 31, 2026 |
| H.C. Wainwright | Analyst unavailable | $345 | $250.25 | +52.9% | Aug 27, 2026 |
| BMO Capital | Analyst unavailable | $319 | $248.85 | +41.4% | Aug 18, 2026 |
| RBC Capital | Luca Issi | $290 | $247.06 | +28.5% | Aug 14, 2026 |
| Barclays | Analyst unavailable | $329 | $246.23 | +45.8% | Aug 14, 2026 |
| Jefferies | Kelly Shi | $333 | $246.23 | +47.6% | Aug 13, 2026 |
| Morgan Stanley | Analyst unavailable | $275 | $253.6 | +21.9% | Jul 23, 2026 |
| RBC Capital | Analyst unavailable | $280 | $267.92 | +24.1% | Jul 7, 2026 |
| Evercore ISI | Analyst unavailable | $329 | $241.83 | +45.8% | May 15, 2026 |
| Barclays | Analyst unavailable | $345 | $238.66 | +52.9% | May 11, 2026 |
| Wells Fargo | Analyst unavailable | $326 | $246.14 | +44.5% | May 8, 2026 |
| Jefferies | Analyst unavailable | $262 | $237.35 | +16.1% | Mar 5, 2026 |
| Stifel Nicolaus | Alex Thompson | $332 | $241.38 | +47.2% | Mar 4, 2026 |
| Wolfe Research | Kalpit Patel | $260 | $231.46 | +15.2% | Mar 2, 2026 |
| Cantor Fitzgerald | Li Watsek | $300 | $231.43 | +33.0% | Mar 2, 2026 |
| Evercore ISI | Josh Schimmer | $324 | $234.07 | +43.6% | Mar 2, 2026 |
| Goldman Sachs | Paul Choi | $255 | $233.5 | +13.0% | Mar 2, 2026 |
| Wedbush | Analyst unavailable | $273 | $218.39 | +21.0% | Feb 12, 2026 |
| Oppenheimer | Analyst unavailable | $262 | $217.93 | +16.1% | Feb 12, 2026 |
| Stifel Nicolaus | Alex Thompson | $325 | $218.04 | +44.1% | Feb 12, 2026 |
| Morgan Stanley | Maxwell Skor | $256 | $221.49 | +13.5% | Feb 12, 2026 |
| Barclays | Eliana Merle | $342 | $238.8 | +51.6% | Jan 27, 2026 |
| RBC Capital | Analyst unavailable | $250 | $205.83 | +10.8% | Jan 20, 2026 |
| Wells Fargo | Derek Archila | $330 | $205.83 | +46.3% | Jan 20, 2026 |
| Wells Fargo | Analyst unavailable | $322 | $208.75 | +42.7% | Jan 9, 2026 |
| Stifel Nicolaus | Alex Thompson | $256 | $201.37 | +13.5% | Dec 11, 2025 |
| Cantor Fitzgerald | Li Watsek | $254 | $209.55 | +12.6% | Oct 13, 2025 |
| RBC Capital | Luca Issi | $230 | $191.49 | +2.0% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $180 | $144.08 | -20.2% | Feb 18, 2025 |
| Bank of America Securities | Tazeen Ahmad | $191 | $151.26 | -15.3% | Sep 23, 2024 |
| Evercore ISI | Gavin Clark-Gartner | $205 | $144.97 | -9.1% | Sep 17, 2024 |
| Oppenheimer | Leland Gershell | $190 | $143.9 | -15.8% | Sep 17, 2024 |
| Citigroup | David Lebowitz | $207 | $139.57 | -8.2% | Sep 17, 2024 |
| Wells Fargo | Derek Archila | $289 | $139.57 | +28.1% | Sep 17, 2024 |
| Bank of America Securities | Tazeen Ahmad | $175 | $142.26 | -22.4% | Sep 16, 2024 |
| Goldman Sachs | Paul Choi | $200 | $142.26 | -11.3% | Sep 16, 2024 |
| Citigroup | David Lebowitz | $178 | $118 | -21.1% | Sep 13, 2024 |
| Oppenheimer | Leland Gershell | $180 | $122.4 | -20.2% | Sep 5, 2024 |
| Jefferies | Kelly Shi | $196 | $128.48 | -13.1% | Aug 13, 2024 |
| Stifel Nicolaus | Alex Thompson | $200 | $137.45 | -11.3% | May 30, 2024 |
| Morgan Stanley | Vikram Purohit | $140 | $124.04 | -37.9% | May 15, 2024 |
| Evercore ISI | Josh Schimmer | $191 | $149.89 | -15.3% | Mar 14, 2024 |
| Wells Fargo | Analyst unavailable | $177 | $118.87 | -21.5% | Jan 3, 2023 |
| Morgan Stanley | Analyst unavailable | $148 | $111.47 | -34.4% | Nov 15, 2022 |
| Leerink Partners | Analyst unavailable | $148 | $110.26 | -34.4% | Nov 14, 2022 |
| Wedbush | Analyst unavailable | $164 | $110.26 | -27.3% | Nov 14, 2022 |
| Bank of America Securities | Tazeen Ahmad | $161 | $117.44 | -28.6% | Mar 20, 2022 |
| Citigroup | David Lebovitz | $187 | $112.39 | -17.1% | Feb 28, 2022 |
| Cowen & Co. | Yaron Werber | $136 | $121.7 | -39.7% | Jan 6, 2022 |
| Canaccord Genuity | Michelle Gilson | $196 | $126.68 | -13.1% | Jul 7, 2021 |
| Cantor Fitzgerald | Alethia Young | $201 | $134.4 | -10.9% | Jun 14, 2021 |
Track every rating change on ASND the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAscendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Historical context
All ASND earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- SNXFY2026 Q3 · September 24, 2026+20.9% EPS-9.9% move
- DRIFY2027 Q1 · September 24, 20260.0% EPS-3.0% move
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
- GISFY2027 Q1 · September 23, 2026+4.6% EPS+1.0% move
- AZOFY2026 Q4 · September 22, 2026+3.6% EPS+3.3% move
Get the ASND recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-09-26T01:51:10.130169+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-26T01:51:10.127526+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-26. For educational purposes only; not investment advice.